Pacientes Colombia cuestiona destino de recursos de salud ante fallas en entrega de medicamentos de Nueva EPS
Nueva EPS recibe cerca de $16 billones anuales de los regímenes contributivo y subsidiado. Foto: Cesar Melgarejo - Portafolio
TL;DR
- Pacientes Colombia is questioning the destination of funds received by Nueva EPS, highlighting the impact on affiliated patients.
- Colsubsidio and Medicarte ceased providing services to Nueva EPS on January 1, 2026, due to pending debts or contract terminations.
- Patients have reported operational failures, unactivated dispensing points, and uncertainty about treatment continuity since January 4.
- Pharmaceutical managers report over $852,000 million in accumulated debts within the sector.
- Nueva EPS receives approximately $16 trillion annually from the contributory and subsidized regimes.
- Denis Silva of Pacientes Colombia questions the use of funds, asking why payments to providers and medication managers are not guaranteed.
- Over 11.5 million affiliates nationwide are affected, facing choices between food and medication.
- Reports indicate Nueva EPS owes $21.3 trillion to hospitals and providers, has $15.2 trillion in unlegalized advances, and a negative equity of $4.4 trillion.
- Pacientes Colombia suggests administrative mismanagement or opacity in resource use.
- The organization demands immediate explanations from Nueva EPS and information from the National Health Superintendence.
- The Attorney General's Office previously certified Nueva EPS's loss of capacity to guarantee the right to health, with over 500 avoidable deaths in 2025 linked to access barriers.